Latest news
ABCL635 Reduced Vasomotor Symptom Frequency and Severity in Phase 2 Trial - Patient Care OnlinePatient Care Online · Mon, 10 Aug 2026 15:11:15 GMTPhase 2 data: ABCL635 reduces frequency, severity of VMS symptoms - Contemporary OB/GYNContemporary OB/GYN · Mon, 10 Aug 2026 14:54:42 GMTAbCellera’s ABCL-635 Cuts Menopause Hot Flashes 83% in Phase II Trial - Yahoo FinanceYahoo Finance · Mon, 10 Aug 2026 13:03:44 GMTAbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile - BioSpaceBioSpace · Mon, 10 Aug 2026 12:40:13 GMTHow Doctors’ Reassurance That Symptoms Are Normal Can Backfire - Bioengineer.orgBioengineer.org · Mon, 10 Aug 2026 10:29:45 GMTType 2 Diabetes Linked to Worse Menopausal Symptoms - Optometry AdvisorOptometry Advisor · Mon, 10 Aug 2026 04:00:00 GMTNew therapy could offer alternative to hormone treatment for menopause symptoms - Drug Discovery NewsDrug Discovery News · Sun, 09 Aug 2026 07:17:49 GMTI Was Hired To Play A Pregnant Woman In Disaster Simulations. No One Knew The Secret I Was Hiding Under My Shirt. - HuffPostHuffPost · Sat, 08 Aug 2026 12:01:04 GMT